We report the syntheses and activities of a wide range of thiazolides [viz., 2-hydroxyaroyl-N-(thiazol-2-yl)amides] against hepatitis B virus replication, with QSAR analysis of our results. The prototypical thiazolide, nitazoxanide [2-hydroxybenzoyl-N-(5-nitrothiazol-2-yl)amide, NTZ] 1 is a broad spectrum antiinfective agent effective against anaerobic bacteria, viruses, and parasites. By contrast, 2-hydroxybenzoyl-N-(5-chlorothiazol-2-yl)amide 3 is a novel, potent, and selective inhibitor of hepatitis B replication (EC(50) = 0.33 μm) but is inactive against anaerobes. Several 4'- and 5'-substituted thiazolides show good activity against HBV; by contrast, some related salicyloylanilides show a narrower spectrum of activity. The ADME properties of 3 are similar to 1; viz., the O-acetate is an effective prodrug, and the O-aryl glucuronide is a major metabolite. The QSAR study shows a good correlation of observed EC(90) for intracellular virions with thiazolide structural parameters. Finally we discuss the mechanism of action of thiazolides in relation to the present results.
We report the syntheses and activities of a wide range of thiazolides [viz., n>an class="Chemical">2-hydroxyaroyl-N-(thiazol-2-yl)amides] against hepatitis B virus replication, with QSAR analysis of our results. The prototypical thiazolide, nitazoxanide [2-hydroxybenzoyl-N-(5-nitrothiazol-2-yl)amide, NTZ] 1 is a broad spectrum antiinfective agent effective against anaerobic bacteria, viruses, and parasites. By contrast, 2-hydroxybenzoyl-N-(5-chlorothiazol-2-yl)amide 3 is a novel, potent, and selective inhibitor of hepatitis B replication (EC(50) = 0.33 μm) but is inactive against anaerobes. Several 4'- and 5'-substituted thiazolides show good activity against HBV; by contrast, some related salicyloylanilides show a narrower spectrum of activity. The ADME properties of 3 are similar to 1; viz., the O-acetate is an effective prodrug, and the O-aryl glucuronide is a major metabolite. The QSAR study shows a good correlation of observed EC(90) for intracellular virions with thiazolide structural parameters. Finally we discuss the mechanism of action of thiazolides in relation to the present results.
Authors: Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple Journal: J Med Chem Date: 2002-06-06 Impact factor: 7.446
Authors: Huiling Yang; Christopher E Westland; William E Delaney; Elizabeth J Heathcote; Victoria Ho; John Fry; Carol Brosgart; Craig S Gibbs; Michael D Miller; Shelly Xiong Journal: Hepatology Date: 2002-08 Impact factor: 17.425
Authors: O Weber; K-H Schlemmer; E Hartmann; Ina Hagelschuer; A Paessens; E Graef; K Deres; S Goldmann; U Niewoehner; J Stoltefuss; D Haebich; H Ruebsamen-Waigmann; Stefan Wohlfeil Journal: Antiviral Res Date: 2002-05 Impact factor: 5.970
Authors: Lennart Eriksson; Joanna Jaworska; Andrew P Worth; Mark T D Cronin; Robert M McDowell; Paola Gramatica Journal: Environ Health Perspect Date: 2003-08 Impact factor: 9.031
Authors: Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva Journal: Bioorg Chem Date: 2020-11-19 Impact factor: 5.275
Authors: Kristina Shigyo; Oksana Ocheretina; Yves Mary Merveille; Warren D Johnson; Jean William Pape; Carl F Nathan; Daniel W Fitzgerald Journal: Antimicrob Agents Chemother Date: 2013-03-18 Impact factor: 5.191
Authors: Thomas Scior; Jorge Lozano-Aponte; Subhash Ajmani; Eduardo Hernández-Montero; Fabiola Chávez-Silva; Emanuel Hernández-Núñez; Rosa Moo-Puc; Andres Fraguela-Collar; Gabriel Navarrete-Vázquez Journal: Curr Comput Aided Drug Des Date: 2015 Impact factor: 1.606